RESEARCH MONOGRAPH · KDC-MN-140

NG2-101

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 2 min read

Our opinion on this compound

31/100

Investigational neurogenic peptide where the literature is too thin for us to have a strong view

Honestly, this is hedge territory. NG2-101 isnt a compound with a substantial peer-reviewed literature footprint that we've been able to thoroughly characterize. The naming convention suggests an investigational neurogenic peptide, and there are a small number of references in adjacent literature, but we havent run this in lab and the public-domain data we'd want to base a strong opinion on isnt there.

What we can say generally: the neurogenic peptide space includes a range of candidates that target either neurotrophin pathways (BDNF or NGF mimetics, p75NTR/TrkA/TrkB modulators), Wnt signaling, or neuroinflammatory modulation as routes to hippocampal neurogenesis. These programs have a mixed history. Some (like the NSI-189 history) have had reasonable Phase 1 and Phase 2 signal that didnt translate to larger trials. Others have been preclinical-only programs that never made the jump to human studies.

Without specific provenance information for NG2-101 we cant tell you which of those buckets it falls into, what the receptor target is, or what the development stage looks like.

What we'd want to see before forming a stronger view: a primary publication characterizing the sequence (or chemical structure if it's not a peptide), a mechanism-of-action paper with receptor binding or activity data, any in vivo neurogenesis or behavioral readouts, and toxicology if any has been published. Without those reference points we're working with too thin a base to write you a useful opinion.

Sourcing realities for any investigational compound in this category: vendor characterization matters more than usual because there's no regulatory-grade reference standard to compare against. Independent mass spec verification is essentially required. And theoretically promising mechanism stories need to be discounted heavily until orthogonal validation exists.

If you have specific literature references for NG2-101 that we should be aware of, the picture might change. For now this is one we'd hedge on rather than overstate. Hand-wavy claims about "neurogenic peptides" without specific receptor targets and replicated readouts are a category we try to be skeptical about by default. Worth tracking, not worth prioritizing as a research tool until the data set fills in.

Evidence: 15
Mechanism: 20
Reliability: 25
Safety: 50
Sourcing: 40
Value: 35
Signal: 30
Staying power: 30

Plain-language summary Intrigue 30 / 100

NG2-101 is an investigational neurogenic peptide. Limited published research. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Investigational neurogenic peptide

An investigational peptide for hippocampal neurogenesis with limited public characterization.

Abstract

NG2-101 is a research peptide marketed for neurogenic applications with limited published characterization. The compound's specific sequence and mechanism are not fully disclosed in peer-reviewed literature; vendor claims center on hippocampal neurogenesis effects similar to BDNF or NGF mimetics. The absence of peer-reviewed characterization is significant; investigators should treat the compound with substantial skepticism and obtain analytical confirmation of identity and purity before any investigational use. There is no formal pharmacokinetic, safety, or efficacy data.

Mechanism of action

Claimed neurogenic activity; mechanism not formally characterized in peer-reviewed literature.

Reported research dose ranges

No reliable data.

References

Limited published characterization. Investigators should treat as experimental.

Read the full monograph

The full reference document is available as a research-use-only PDF download. Note: PDFs for newly added compounds may take a few hours to propagate after this article was published.

KDC-MN-140

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

NG2-101

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs